NYSEARCA:ATNM - NYSE Arca - US00507W2061 - Common Stock - Currency: USD
Overall ATNM gets a fundamental rating of 2 out of 10. We evaluated ATNM against 556 industry peers in the Biotechnology industry. The financial health of ATNM is average, but there are quite some concerns on its profitability. ATNM has a expensive valuation and it also scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -66.3% | ||
ROE | -177.13% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -8.57 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 9.35 | ||
Quick Ratio | 9.35 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NYSEARCA:ATNM (7/21/2025, 4:32:48 PM)
After market: 1.6606 -0.03 (-1.74%)1.69
-0.02 (-1.17%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | N/A | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 2.05 | ||
P/tB | 2.05 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -66.3% | ||
ROE | -177.13% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 0% | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 9.35 | ||
Quick Ratio | 9.35 | ||
Altman-Z | -8.57 |